Goldman Sachs raised the firm’s price target on Kiniksa (KNSA) to $55 from $45 and keeps a Buy rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KNSA:
- Kiniksa Pharmaceuticals Reports Strong Q3 2025 Growth
- Kiniksa Pharmaceuticals’ Earnings Call Highlights Growth and Optimism
- Kiniksa Pharmaceuticals: Strong Q3 Performance and Growth Potential Justify Buy Rating
- Kiniksa riases FY25 ARCALYST net product revenue view $670M-$675M
- Kiniksa expects current operating plan to remain cash flow positive